MMP-12 Inhibitors Inverse Eosinophilic Inflammation-Mediated Bronchial Fibrosis in Murine Models of Pulmonary Airway Obstruction
Cells · 2025
DOI: 10.3390/cells14171307 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Chandra Sekhar Kathera und 2 weiteren Autor:innen. Beteiligte Einrichtung: John W. Deming Department of Medicine, Tulane Eosinophilic Disorders Center (TEDC), Section of Pulmonary Diseases, Tulane University School of Medici…. Hauptthemen laut MEDLINE: Matrix Metalloproteinase 12, Inflammation, Matrix Metalloproteinase Inhibitors, Airway Obstruction. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH.
Abstract (Originalsprache)
Matrix metalloproteinases (MMPs) are a major group of proteases known to regulate the turnover of the extracellular matrix (ECM). We observed that induced MMP-12 promotes eosinophilic inflammation-related epithelial cell mesenchymal transition (EMT), bronchial fibrosis, and airway obstruction in an allergen-exposed mouse model of chronic airway diseases in allergen-exposed mice and in airway-specific CC10-IL-13-overexpressed mice. Our histological analysis showed that the parabronchial and perivascular accumulation of eosinophils, fibroblasts, and collagen is significantly decreased in MMP-12−/− allergen-exposed mice and airway-specific rtTA-MMP-12−/−CC-10-IL-13-overexpressed mice compared to allergen-exposed wild-type mice and rtTA-CC10-IL-13-overexpressed mice. ELISA and Western blot analyses validated these histological findings, demonstrating that EMT and profibrotic protein levels were significantly decreased in allergen-challenged MMP-12−/− mice and rtTA-MMP-12−/−CC10-IL-13-overexpressed mice in comparison to the allergen-exposed wild-type mice and rtTA-CC10-IL-13-overexpressed mice. In addition, we also observed that allergen-challenged MMP-12−/− mice have improved resistance and compliance compared to allergen-challenged wild-type mice. Most importantly, we show that treatment with MMP-12 inhibitors (PF-00356231 and MMP408) restricts the induction and progression of bronchial fibrosis and airway restrictions in allergen-exposed mice and airway-specific rtTA-CC10-IL-13 mice compared to the respective control mice. Taken together, the novelty of these findings lie in the fact that induced MMP-12 regulates eosinophilic inflammation-induced bronchial fibrosis and associated airway restriction, which may be reduced by treatment with MMP-12 inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- John W. Deming Department of Medicine, Tulane Eosinophilic Disorders Center (TEDC), Section of Pulmonary Diseases, Tulane University School of Medicine, New Orleans, LA 70112, USA.
ORCID-Profile: Chandra Sekhar Kathera, Chandra Sekhar Yadavalli
Förderung
- NIAID NIH HHS
- NIH
Zitieren
APA
Kathera, C. S., Yadavalli, C. S., & Mishra, A. (2025). MMP-12 Inhibitors Inverse Eosinophilic Inflammation-Mediated Bronchial Fibrosis in Murine Models of Pulmonary Airway Obstruction. Cells. https://doi.org/10.3390/cells14171307
Vancouver
Kathera CS, Yadavalli CS, Mishra A. MMP-12 Inhibitors Inverse Eosinophilic Inflammation-Mediated Bronchial Fibrosis in Murine Models of Pulmonary Airway Obstruction. Cells. 2025. doi:10.3390/cells14171307
BibTeX
@article{Kathera2025,
author = {Kathera, Chandra Sekhar and Yadavalli, Chandra Sekhar and Mishra, Anil},
title = {MMP-12 Inhibitors Inverse Eosinophilic Inflammation-Mediated Bronchial Fibrosis in Murine Models of Pulmonary Airway Obstruction},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14171307}
}
EUVIMED